Latest news

• AbbVie is not looking at another big acquisition, says CEO

  Pancreatic enzyme replacement product Creon also had a strong quarter, rising 47% to $148m.

• AbbVie sales jump on strong Humira gains

  Investors have been keen to see substance in AbbVie beyond Humira - which loses patent protection in 2016 - and Gonzalez emphasised double-digit gains for its specialty products including Synthroid, Creon, Zemplar ... Pancreatic enzyme replacement

• AbbVie expects Humira to drive growth in inaugural guidance

  Top of the list in the speciality division is testosterone replacement therapy AndroGel – 31 per cent to $1.15bn in 2012 – with support from Creon (pancrelipase) for pancreatic insufficiency and hypothyroidism

• Abbott wins FDA approval for infant CF dose

  Abbott has secured approval for an infant-specific dose of CREON (pancrelipase) to treat exocrine pancreatic insufficiency caused by cystic fibrosis (CF). ... The pancreatic enzymes in CREON capsules work directly in the intestines to help break down fats

• Abbott plans Solvay layoffs

  Solvay's product portfolio includes the testosterone gel AndroGel, the progesterone capsule Prometrium, and the pancreatic enzyme replacement therapy Creon (pancreatin).